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Summary
Met, the receptor for hepatocyte growth factor (HGF), is activated in human cancer by both ligand-dependent and
-independent mechanisms. We engineered a soluble Met receptor (decoy Met) that interferes with both HGF binding to
Met and Met homodimerization. By lentiviral vector technology, we achieved local or systemic delivery of decoy Met in
mice. We provide evidence that in vivo expression of decoy Met (1) inhibits tumor cell proliferation and survival in a variety
of human xenografts, (2) impairs tumor angiogenesis by preventing host vessel arborization, (3) suppresses or prevents
the formation of spontaneous metastases, and (4) synergizes with radiotherapy in inducing tumor regression, without (5)
affecting housekeeping physiological functions in the adult animal.
Introduction zawa et al., 1994; Yanagita et al., 1993; Galimi et al., 1994;
Matsumoto and Nakamura, 1997). It is, however, clear that HGF/
Hepatocyte growth factor (HGF, also known as scatter factor) Met signaling is exploited by tumors to grow, survive, and ex-
is a pleiotropic cytokine of mesenchymal origin that controls pand, mimicking developing organs or healing wounds (Birch-
cell proliferation, survival, motility, and differentiation in a variety meier et al., 2003; Comoglio and Trusolino, 2002; Vande Woude
of tissues, including epithelial, endothelial, neuronal, and hemo- et al., 1997).
poietic cells (Rubin et al., 1993; Zarnegar and Michalopoulos, While the Met receptor is expressed by most tissues of
1995; Tamagnone and Comoglio, 1997). The coordinated or- epithelial, hemopoietic, and neuronal origin, HGF is secreted
chestration of these biological processes by HGF results in a by mesenchymal cells, but it accumulates ubiquitously in tissues
specific genetic program known as “invasive growth” (reviewed due to its high affinity for extracellular matrix (Kobayashi et al.,
by Trusolino and Comoglio, 2002). This complex program has 1994; Lyon et al., 1994). Met overexpression is a common event
evolved primarily to master vital morphogenetic processes dur- in human cancer (reviewed by Trusolino and Comoglio, 2002),
and may determine ligand-independent receptor activationing embryo development and organ formation (Woolf et al.,
1995; Takayama et al., 1996; Andermarcher et al., 1996). Experi- (Wang et al., 2001) or increased sensitivity to environmental
HGF (Pennacchietti et al., 2003).mental deletion of the hgf gene—or of the gene encoding its
high affinity receptor, the tyrosine kinase Met—results in placen- Various approaches have been explored to inhibit HGF or
Met in experimental systems, including neutralization of HGFtal and hepatic abnormalities leading to in utero embryo death
(Schmidt et al., 1995; Uehara et al., 1995; Bladt et al., 1995). by monoclonal antibodies (Cao et al., 2001), ribozyme-mediated
downregulation of HGF/Met expression (Jiang et al., 2001, 2003;In the adult organism, the physiologic role of the HGF path-
way is less well understood, although several lines of evidence Abounader et al., 2002; Herynk et al., 2003; Kim et al., 2003),
impairment of receptor dimerization by dominant-negative Metsuggest that it may be involved in wound healing, tissue regener-
ation, hemopoiesis, and tissue homeostasis in general (Miya- (Firon et al., 2000; Furge et al., 2001), inhibition of Met tyrosine
S I G N I F I C A N C E
Tyrosine kinase inhibitors and antiangiogenic agents have recently shown great promise in cancer therapy. However, involvement
of tyrosine kinase pathways in important physiologic processes has raised concerns about the toxicity of tyrosine kinase inhibitors.
Similarly, pure antiangiogenic agents have proved less effective than anticipated in early clinical trials, suggesting that simultaneous
targeting of host vessels and cancer cells may be more effective than antiangiogenic therapy alone. Here, we show that inhibition
of a single tyrosine kinase receptor achieves concomitant suppression of cancer cell proliferation, survival, and invasion, and of
host angiogenesis, without interfering with normal physiologic functions. These data point to Met as an ideal target for antineoplastic
therapy, and provide proof-of-concept for further clinical testing of HGF/Met antagonists.
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kinase activity by small molecule inhibitors (Sattler et al., 2003; full-size Met (not shown). Thus, decoy Met interacts with high
affinity with both HGF and full-size Met.Christensen et al., 2003; Wang et al., 2003), and ligand displace-
ment by a competitive inhibitor of HGF (reviewed by Matsumoto
Decoy Met inhibits Met activation mediated by HGFand Nakamura, 2003).
or by ligand-independent mechanismsIn the present study, we employed an alternative approach
To test whether the engineered antagonists could inhibit ligand-based on (1) a soluble Met receptor (Michieli et al., 1999) and
induced Met activation, we stimulated lentiviral vector-trans-(2) an improved lentiviral vector technology (Follenzi et al., 2000).
duced cells with recombinant HGF, and then determined theThe data presented here not only point to Met as an ideal target
extent of Met tyrosine phosphorylation. In MDA-MB-435 cells,for cancer therapy, but also suggest that the extracellular portion
cells transduced with NK4 HGF or decoy Met lentivirus showedof the Met receptor is a promising therapeutic agent by itself.
markedly reduced sensitivity to HGF stimulation compared to
cells transduced with control lentivirus (Figure 1E, MDA panel).Results
Similar results were obtained with A549 cells and HUVECs, thus
suggesting that both NK4 HGF and decoy Met prevent HGF-Engineering of decoy Met
induced Met activation in a variety of cellular models. However,To generate a soluble HGF receptor, we engineered a recombi-
Met is often activated in cancer by HGF-independent mecha-nant protein corresponding to the entire extracellular domain
nisms (reviewed by Trusolino and Comoglio, 2002). We thereforeof Met, truncated before the transmembrane domain (Figure
tested whether NK4 HGF or decoy Met could inhibit Met activa-1A). As a control, we also engineered a truncated form of HGF,
tion induced by (1) overexpression or (2) oncogenic point muta-known as NK4 HGF, which has been shown to compete with
tion in different cell systems.HGF in Met binding (Matsumoto and Nakamura, 2003). A Myc-
In COS cells, transient overexpression of exogenous Metepitope tag and a poly-histidine tag were added at the C termi-
results in spontaneous dimerization and autoactivation due tonus of both molecules. The cDNAs for the engineered molecules
very high protein levels. In this model, coexpression of decoywere subcloned into the pRRLsin.PPT.CMV.Wpre lentiviral vec-
Met—but not NK4 HGF—significantly reduced wild-type Mettor (Follenzi et al., 2000; Supplemental Figure S1 at http://www.
phosphorylation (Figure 1E, COS panel). In GTL16 gastric carci-cancercell.org/cgi/content/full/6/1/61/DC1). Into the same vec-
noma cells, Met is constitutively activated due to natural recep-tor, we also subcloned the cDNA for human HGF. Recombinant
tor overexpression (Giordano et al., 1989). In this system too,viral particles from recombinant vectors were produced in large
expression of decoy Met dramatically reduced constitutive Metscale and used to transduce a panel of human tumor cell lines
tyrosine phosphorylation, while NK4 HGF was not effective (Fig-
(MDA-MB-435 and MDA-MB-435-4, human mammary carci-
ure 1E, GTL16 panel).
noma; A549, human lung carcinoma) and primary human umbili-
In hereditary and sporadic papillary carcinomas of the kid-
cal vein endothelial cells (HUVECs). The different recombinant ney, in sporadic hepatocellular carcinomas, and in head and
factors reached comparable concentrations in the conditioned neck primary tumors and metastases, Met has been found to
medium of transduced cells, approximately 30–60 nM in 72 hr be activated by point mutation (Schmidt et al., 1997; Park et
(Supplemental Figure S2). al., 1999; Di Renzo et al., 2000). To test whether NK4 HGF
or decoy Met could interfere with point mutation-induced Met
Decoy Met binds at high affinity to both HGF activation, we transduced TOV-112D human ovarian carcinoma
and full-size Met cells (which lack Met expression; see below) with a lentiviral
Starting from the conditioned medium of lentiviral vector-trans- vector encoding wild-type or mutated Met, or an empty vector
duced tumor cells, NK4 HGF and decoy Met were purified to as control. Cells overexpressing mutant Met (M1250T) displayed
homogeneity by affinity chromatography (Figure 1B), and their constitutive tyrosine phosphorylation (Figure 1E, TOV panel).
ability to bind Met or HGF, respectively, was analyzed by ELISA These cells were further transduced with empty, NK4 HGF, or
(Figure 1C). Purified Fc-Met chimera was used as a control for decoy Met vector, and the extent of Met tyrosine phosphoryla-
HGF binding (Mark et al., 1992). NK4 HGF bound Met with tion was determined by immunoblotting. Once again, decoy Met
approximately one log less affinity compared to HGF (HGF, KD could efficiently prevent point mutation-induced Met activation,
0.035 nM; NK4 HGF, KD  0.326 nM). In contrast, human HGF while NK4 HGF was not effective (Figure 1E, TOV panel). There-
bound decoy Met with a KD of 0.049 nM, a value which corre- fore, consistent with the biochemical data presented above,
sponds approximately to the in vivo affinity of HGF for bona decoy Met is a soluble HGF antagonist capable of interfering
fide Met (Matsumoto et al., 1998). with both HGF-induced and ligand-independent Met activation.
Since the extracellular portion of Met is conceivably involved
in receptor homodimerization, we also tested the ability of decoy Decoy Met inhibits the pleiotropic effects of HGF in vitro
Met to interact with full-size Met in (1) coimmunoprecipitation In a first experimental approach, we tested the ability of HGF
experiments and (2) ELISA binding assays. In lentiviral vector- antagonists to inhibit HGF-dependent biological activity on tu-
transduced MDA-MB-435 cells, decoy Met (but not NK4 HGF) mor cells in a variety of in vitro assays. We subjected lentiviral
coimmunoprecipitated with endogenous Met, and vice versa vector-transduced cells to (1) a proliferation assay, (2) a survival
(Supplemental Figure S3). In ELISA binding assays, purified assay, (3) a Matrigel invasion assay, (4) a branching morphogen-
decoy Met bound Fc-Met at high affinity (Figure 1D), following esis assay, and (5) a “scratch” assay, either in the absence or
a biphasic curve (first site, KD  0.058 nM; second site, KD  presence of recombinant HGF. This analysis revealed that both
2.840 nM). Consistent with this, we observed that two distinct NK4 HGF and decoy Met—at the concentrations reached by
isolated subdomains of decoy Met, the SEMA domain and the lentiviral vector-mediated expression—effectively inhibited
HGF-induced DNA synthesis (Figure 2A), protection againstIPT region, conserve the ability of coimmunoprecipitating with
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Figure 1. Engineering of a soluble Met receptor
A: Schematic representation of the recombinant
proteins used in this study. SEMA, semaphorin do-
main; MRS, Met-related sequence; IPT 1-4, immu-
noglobulin-plexin-transcription factor domain
1-4; TM, trans-membrane domain; KD, kinase do-
main; CT, C-terminal tail; ME, Myc epitope; PH,
poly-His; HL, hairpin loop; K 1-4, kringle 1-4; PL,
protease-like domain. The red triangles indicate
the proteolytic site dividing the  chain (left) from
the  chain (right).
B: Coomassie staining of NK4 HGF and decoy
Met purified by affinity chromatography and re-
solved by SDS-PAGE in nonreducing conditions.
Starter, conditioned medium prior to purification.
C: Ligand-receptor ELISA binding assay: HGF on
Fc-Met (in green); HGF on decoy Met (in red);
NK4 HGF on Fc-Met (in blue).
D: Receptor-receptor ELISA binding assay: de-
coy Met on Fc-Met.
E: Inhibition of Met activation induced by HGF
stimulation (MDA-MB-435 cells), receptor overex-
pression (COS and GTL16 cells), or oncogenic
point mutation (TOV-112D cells). E, empty vector;
M, full-size Met; D, decoy Met; N, NK4 HGF; pY,
phosphotyrosine; CTRL, cells transduced with
empty vector; wt, wild-type; M1250T, mutant Met
bearing the M1250T amino acid substitution. The
higher Met band (p170 Met) corresponds to un-
processed Met, while the lower band (p145 Met)
is the mature form of Met. Different cell lines may
display different patterns of p170/p145 phos-
phorylation.
apoptosis (Figure 2B), Matrigel invasion (Figure 2C), branching lial cell migration and morphogenesis. Lentiviral vector-trans-
morphogenesis (Figure 2D), and scratch repair (Figure 2E), thus duced HUVECs were analyzed for their ability (1) to migrate
demonstrating that the engineered antagonists can functionally through a fibronectin layer (Figure 3A) and (2) to form capillary-
neutralize the effects of HGF on living cells. However, in Matrigel like branched structures in a collagen gel (Figure 3B), in the
invasion assays using GTL16 gastric carcinoma cells, in which, presence of no factor, recombinant vascular endothelial growth
as described above, Met is constitutively activated, only decoy factor (VEGF), recombinant HGF, or both VEGF and HGF. This
Met inhibited cell migration in the absence of HGF, thus con- analysis revealed that VEGF and HGF cooperate in inducing
firming that decoy Met—but not NK4 HGF—is capable of endothelial cell motility and particularly in promoting capillary
blocking receptor activation in a dominant-negative fashion (Fig-
branching (see Supplemental Figure S4 at http://www.cancercell.ure 2F).
org/cgi/content/full/6/1/61/DC1 for representative images). In
both assays, decoy Met inhibited invasion mediated by HGFDecoy Met impairs HGF-induced endothelial cell
but not by VEGF, indicating that its activity is specific for themigration and branching
HGF/Met pathway. In contrast, as previously reported (Kuba etSince HGF is a potent angiogenic factor (Bussolino et al., 1992),
we analyzed the effect of NK4 HGF and decoy Met on endothe- al., 2000), NK4 HGF inhibited equally well HGF- or VEGF-medi-
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Figure 2. Decoy Met inhibits the pleiotropic activ-
ities of HGF on tumor cells
A: Mitogenic assay. Lentiviral vector-transduced
tumor cells were stimulated with either recombi-
nant HGF or no factor, and DNA synthesis was
determined by [3H]-thymidine incorporation.
C.P.M., counts per minute; empty v., empty
vector.
B: Survival assay. Tumor cells were preincubated
with either recombinant HGF or no factor, and
then cultured either in the presence or absence
of staurosporine. Survival in the absence of stau-
rosporine was not affected by NK4 HGF or decoy
Met, and is not shown. Apoptosis is expressed in
arbitrary units (a.u.).
C: Matrigel invasion assay. Tumor cells were ana-
lyzed for their ability to invade a Matrigel layer,
either in the presence or absence of recombi-
nant HGF.
D: Collagen invasion assay. Tumor cells were ex-
amined for their ability to form branched tubules
in response to HGF stimulation. Values (mean 
SD) indicate the percentage of “sprouted” colo-
nies over the total.
E: Scratch assay using a confluent cell mono-
layer. Cells were wounded and then incubated
either in the presence or absence of recombi-
nant HGF. Values (mean SD) indicate the num-
ber of cells that have migrated over the original
margins (in red).
F: Matrigel invasion assay using tumor cells natu-
rally overexpressing Met. The number of invading
cells was determined as described above.
Throughout the figures, statistical significance
(experimental versus control value) is indicated
by a single (p 0.05) or double (p 0.01) asterisk.
ated HUVEC migration and branching. In this regard, it should reduced tumor weight, although to a lesser extent (1.3-fold, p
0.0453). Autopsy revealed that 40% of the animals in the controlbe noted that NK4 HGF has been found to inhibit angiogene-
sis independently of Met (Matsumoto and Nakamura, 2003), group developed pulmonary metastases, while all mice of the
decoy Met group and 80% of the NK4 HGF group were metasta-and to share remarkable structural homology with angiostatin
(O’Reilly et al., 1994). sis-free. Symmetrically, mice injected with cells transduced with
HGF lentiviral vector had a much higher tumor weight (1.9-fold,
p  0.0023) and developed more metastases (30.8-fold, p Decoy Met inhibits tumor growth
and metastasis in mice 0.0031). Similar results were obtained with A549 lung carcinoma
cells (Figure 4B), and with MDA-MB-435-4 mammary carci-We next tested the biological effects of Met activation (by HGF)
or inhibition (by NK4 HGF or decoy Met) in ex vivo tumorigenesis noma cells (Figure 4C), a more metastogenic variant of MDA-
MB-435 (Trusolino et al., 2001).assays in mice. CD-1 nu/ mice were injected subcutaneously
with different tumor cell lines transduced in vitro with the various Interestingly, histological analysis of lungs revealed remark-
able biological differences between micrometastases found inlentiviral vectors, and injected animals were monitored for tumor
development. After 50 days, experimental tumors were ex- the empty vector, NK4 HGF, and HGF groups (Supplemental
Figure S5). In the control group, metastatic lesions were mostlytracted for analysis, and lungs were contrasted with India ink
to highlight metastases. Following metastasis scoring, lungs small, parenchimatic, and sometimes infiltrated by lymphoid
cells. In the NK4 HGF animals, micrometastases were poor inwere processed for histological analysis.
In experiments using MDA-MB-435 mammary carcinoma infiltrated cells, but appeared well delimited and highly apo-
ptotic. In contrast, metastases in the HGF group appeared muchcells (Figure 4A), decoy Met dramatically reduced tumor weight
compared to the control (5-fold, p  0.0001). Also, NK4 HGF larger, mostly embolic, and free of infiltrate. Furthermore, HGF
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end, we subcutaneously injected MDA-MB-435-4 human
mammary carcinoma cells into CD-1 nu/mice, and then moni-
tored animals for tumor appearance. After two weeks, all mice
bearing tumors of approximately 100 mm3 were selected and
randomly divided into four groups (n  6). High-titer lentiviral
vector preparations were injected intratumorally, and tumor vol-
ume was measured every third day. After 18 days, mice were
subjected to autopsy.
While tumors injected with empty vector enlarged more than
6-fold during the course of the experiment, injection of NK4
HGF or decoy Met almost completely arrested the growth of
the neoplastic mass (NK4 HGF, p  0.0001; decoy Met, p 
0.0001; Figure 5A). Symmetrically, HGF accelerated tumor
growth by 1.6 times compared to the control (p  0.0032).
Similar results emerge from analysis of tumor weight (Figure 5B).
Immunofluorescence analysis of frozen tumor sections revealed
widespread high expression of all the exogenous transgenes
(Supplemental Figure S6). To determine the presence of meta-
static lesions, we analyzed serial lung sections stained with
hematoxylin and eosin. We found micrometastases in all experi-
mental groups except decoy Met (Figure 5C).
We also determined the proliferative index (Ki67; Figure 5D)
and apoptotic index (TUNEL; Figure 5E) of cells within the tu-
mors. Remarkably, decoy Met reduced tumor cell proliferation
by almost 2-fold (p 0.0001) and increased apoptosis approxi-
mately 3.7 times (p  0.0001). NK4 HGF also decreased tumor
cell mitotic index (2.1-fold, p  0.0001) and augmented apo-
ptotic cell death (2.3-fold, p 0.0001). HGF achieved the oppo-
site effect on both proliferation (1.2-fold higher, p  0.0015)
and apoptosis (3-fold lower, p  0.0001).
Figure 3. Decoy Met inhibits HGF-induced endothelial cell motility and mor-
Decoy Met inhibits angiogenesis and impairs tumorphogenesis
vessel arborizationA: Fibronectin invasion assay. HUVECs were analyzed for their ability to
To determine vessel distribution within the transduced neoplas-invade a fibronectin layer in the presence of no factor, VEGF, HGF, or both
HGF and VEGF. E, empty vector; N, NK4 HGF; D, decoy Met; CTRL, control; tic lesions described above, we stained tumor sections with
V  H, VEGF  HGF. antibodies against the CD31 endothelial marker, and analyzed
B: Branching morphogenesis assay. Preformed HUVEC spheroids were stimu- them by fluorescence microscopy. Three distinct parameters
lated as in A and global tubule elongation was quantified by summing the
were determined (Figure 5F): vessel density, total vessel area,length of all tubules in each colony analyzed.
and mean lumen area. Strikingly, this analysis revealed that HGFC: Branched colony complexity from the experiment described in B is ex-
pressed by the number of branch points per colony (see Supplemental increased vessel density by 1.7 times (p  0.0134), but at the
Figure S4 at http://www.cancercell.org/cgi/content/full/6/1/61/DC1 for same time decreased the size of lumina by approximately the
representative images).
same order (p  0.0046), thus not significantly changing total
vessel area. In other words, HGF caused tumor vessels to be
higher in number, but smaller in diameter, thus resulting in
greater arborization. Conversely, decoy Met decreased vesselalso promoted the formation of several “exploded” metastatic
density by approximately 11 times (p  0.0178), but reducedemboli invading the lung parenchima.
total vessel area only 3.2-fold (p  0.0224), thus resulting inWe wondered whether the absence of metastatic lesions in
dramatically higher lumen caliber (approximately 3.5-fold, p the decoy Met group was merely due to reduced tumor size.
0.0192; see Figure 5G for representative images). Interestingly,We therefore reperformed the same analysis using MDA-MB-
and consistent with a different mechanism of angiogenesis inhi-435-4 cells on a panel of randomized animals that were all
bition, NK4 HGF reduced both vessel density (1.4-fold, p bearing large tumors of the same volume (approximately 4,000
0.0017) and mean lumen area (1.4-fold, p  0.0016), thus re-mm3) at the time of sacrifice, regardless of the time required by
sulting in fewer and smaller vessels within the tumor.the tumor to reach such volume (Figure 4D). In this analysis as
well, no metastasis at all could be found in the decoy Met
Concomitant action on tumor and endothelial cellsgroup, suggesting that decoy Met prevents tumor cell spreading
by decoy Met results in optimal inhibitiondirectly and independently of its parallel effect on tumor growth.
of tumor growth
To determine whether the sole inhibition of vessel arborizationDecoy Met blocks the growth and dissemination
by decoy Met could have biological consequences on tumorof established tumors
growth, we performed ex vivo tumorigenesis assays using theWe next analyzed whether NK4 HGF or decoy Met could inter-
fere with growth and invasion of an established tumor. To this TOV-112D human ovarian carcinoma cell line, which lacks Met
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Figure 4. Ex vivo expression of decoy Met inhibits
tumor growth and metastasis in mice
A–C: Cells were transduced with the indicated
lentiviral vector and then injected subcutane-
ously into nude mice. After eight weeks, tumor
weight (left Y axis, gray) and pulmonary metasta-
ses (right Y axis, black) were determined. Empty
v., empty vector. T.I., tumor incidence; M.I., me-
tastasis incidence. See also Supplemental Figure
S5 at http://www.cancercell.org/cgi/content/
full/6/1/61/DC1 for metastasis histology.
D: Metastasis analysis on mice bearing MDA-MB-
435-4 tumors measuring 4,000 mm3 at the time
of lung extraction. Left Y axis, number of metasta-
ses (black); right Y axis, time required by tumors
to reach a 4,000 mm3 volume (white).
expression as determined by both Western blot and RT-PCR NK4 HGF groups seemed to have recovered from their initial
reserve, and grew at a high rate. By the end of the experiment,analysis (Figure 6A). We transduced TOV-112D cells with the
full panel of lentiviral vectors, and then injected them subcutane- no statistically significant difference in tumor volume or weight
could be measured between the decoy Met or NK4 HGF groupously into nude mice. Tumor growth was monitored as de-
scribed above for 20 days, and then tumors were extracted for and the empty vector group. In contrast, HGF dramatically in-
creased both tumor volume (5.3 times, p  0.0422) and weightanalysis.
We first determined whether mouse vessels within the tumor (4.9 times, p  0.0378). Western blot analysis on tumor lysates
ruled out the possibility that cancer cells had lost decoy Metwere expressing the Met receptor. Confocal immunofluores-
cence analysis revealed complete signal overlapping between or NK4 HGF expression during the course of the experiment
(Supplemental Figure S7B).CD31 and mouse Met staining (Figure 6B). By RT-PCR analysis,
we also determined that cancer cells in all tumors had not This phenomenon can be explained if we hypothesize that
inhibition of angiogenesis by decoy Met or NK4 HGF applies aacquired met expression during the course of the experiment
(Supplemental Figure S7A). selective pressure on tumor cells. During an early “crisis” phase,
cancer cells that have a reduced vascular demand (Rak et al.,Next, we determined vessel distribution as performed for
MDA-MB-435-4 tumors using anti-CD31 antibodies (Figure 2002) are selected for, and subsequently take over the remaining
tumor cell population. In contrast, HGF provides an advantage6C). We observed that: (1) decoy Met decreased vessel density
(5-fold, p  0.0001), increased mean lumen area (2.1-fold, p  to tumor cells, because it promotes angiogenesis. All in all, we
can conclude that: (1) HGF sustains the growth and expansion0.0033), and reduced total vessel area (2.4-fold, p  0.0002);
(2) NK4 HGF decreased vessel density (2-fold, p  0.0003), of a tumor, even when tumor cells do not express the HGF
receptor, because it promotes host vessel arborization; andmean lumen area (1.3-fold, p  0.0311), and total vessel area
(2.7-fold, p  0.0001); and (3) HGF increased vessel density (2) the sole impairment of angiogenesis by decoy Met or NK4
HGF—without a concomitant action on tumor cells—is insuffi-(1.7-fold, p  0.0006) and decreased mean lumen area (1.5-
fold, p  0.0065), but did not significantly augment total vessel cient to determine a persistent inhibition of tumor growth, at
least in the biologic system analyzed.area (1.1-fold, p  0.0769).
This remarkable impairment of vessel morphology by decoy
Met resulted in a net 20% decrease in tumor incidence and in Systemic inhibition of HGF/Met prevents tumor growth
and metastasis without substantially affectinga significant delay of tumor formation (2.4-fold, p  0.0029;
Figure 6D). Similarly, inhibition of vessel formation by NK4 HGF housekeeping physiological functions
In our next approach, we compared the effects of systemicalso decreased tumor incidence by 20%, and significantly de-
layed tumor formation (2.2-fold, p  0.0259). Consistent with HGF/Met inhibition on tumor versus normal tissues. Systemic
administration of lentiviral vectors is a powerful approach tothese observations, promotion of vessel arborization by HGF
significantly accelerated tumor formation (2-fold, p  0.0352). obtain sustained plasmatic levels of a secreted factor (Follenzi
et al., 2002). To this end, we injected i.v. a panel of CD-1 nu/However, once they appeared, all tumors of the decoy Met and
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Figure 5. Decoy Met inhibits the growth, vascu-
larization, and dissemination of established
tumors
A: Tumor burden analysis. Tumors of the same
size (approximately 100 mm3 at day 0) were re-
peatedly injected with the indicated lentiviral
vectors, and tumor volume was measured every
3 days. The numbers in red correspond to the
days of lentivirus injection. LV, lentiviral vector.
B: Tumor weight analysis of the experiment de-
scribed in A. E, empty vector; H, HGF; N, NK4
HGF; D, decoy Met.
C: Histological analysis of pulmonary metastases
on lung sections stained with hematoxylin and
eosin. A representative microscopic field for
each group is shown. Arrows indicate the posi-
tion of the metastatic lesion. Metastasis inci-
dence is shown in parentheses. The red bar is a
100 	m marker.
D: Tumor proliferation index analysis (% Ki67-posi-
tive cells).
E: Tumor apoptotic index analysis (% TUNEL-posi-
tive cells).
F: Tumor vessel analysis: vessel density, number
of vessels per mm2; total vessel area, percentage
of the tumor section occupied by vascular tissue;
mean lumen area, average section of a vessel
in 	m2.
G: Representative images of the analysis de-
scribed in F. The yellow bar is a 100 	m marker.
mice with highly concentrated lentiviral vector preparations, and tions. We measured various clinical and biological parameters,
including ability to repair a cutaneous wound, complete he-obtained three distinct sets of animals expressing stable (Sup-
plemental Figure S8 at http://www.cancercell.org/cgi/content/ mochrome and white blood cell formula, hemoglobin concentra-
tion, coagulation properties, liver and kidney function enzymes,full/6/1/61/DC1) picomolar plasma concentrations of HGF (40–
100 pM), NK4 HGF (24–41 pM), or decoy Met (11–50 pM), and other markers (Table 1 and Supplemental Table S1). This
analysis revealed that most physiological parameters were leftplus one set of control animals (empty vector). Considering that
endogenous HGF is found in normal mice at about 5–6 pM (Xue substantially unaffected, with a few remarkable exceptions in
the NK4 HGF group. In fact, NK4 HGF increased both red (1.2-et al., 2002), the observed factor concentrations are certainly
significant from a biological viewpoint. fold, p  0.0001) and white (1.1-fold, p  0.0279) blood cell
numbers, while it decreased platelet concentration (1.2-fold,Between three and five weeks after injection, mice were
subjected to a series of tests aimed at determining whether p  0.0278). Microscopy analysis revealed that this increment
in white blood cells was contributed mainly by granulocytessustained expression of exogenous HGF or HGF antagonists
was perturbing their major housekeeping physiological func- (not shown). NK4 HGF also increased hemoglobin concentration
CANCER CELL : JULY 2004 67
A R T I C L E
Figure 6. Decoy Met delays the growth of tumor
cells lacking the HGF receptor by impairing host
vessel arborization
A: Analysis of Met protein and met mRNA expres-
sion in human tumor cell lines and primary endo-
thelial cells. WB, Western blot; IP, immunoprecipi-
tation; RT-PCR, reverse transcriptase polymerase
chain reaction; app, human housekeeping
gene encoding -amyloid precursor protein
(see also Supplemental Figure S5 at http://www.
cancercel l .org/cgi/content/fu l l /6/1/61/
DC1).
B: Confocal immunofluorescence analysis of
CD31 and mouse Met expression on TOV-112D
tumors. Frozen sections were costained with anti-
mouse CD31 antibodies (in red) and anti-mouse
Met antibodies (plain or epitope-competed; in
green). The yellow bar is a 100 	m marker.
C: Tumor vessel analysis of TOV-112D tumor sec-
tions. CD31 staining was analyzed as described
for Figure 5F.
D: Tumorigenesis assay using lentiviral vector-
transduced TOV-112D cells. Mice were injected
with lentiviral vector-injected cells and then
monitored every two days for tumor appear-
ance. Empty v., empty vector.
(1.1-fold, p  0.0004; Table 1). Since these changes were not grew at a lower rate. However, tumor incidence was not re-
observed in the decoy Met group, nor was a symmetric effect duced, suggesting that the plasmatic concentrations of NK4
elicited by HGF, hemochrome alterations induced by NK4 HGF HGF reached in these mice—in contrast with those obtained
are conceivably a result of Met-independent mechanisms. No locally by direct tumor injection—may be too low to achieve a
other parameter analyzed was significantly changed compared significant tumor inhibition.
to the control, either in the NK4 group or in the other two. Autopsy (see Table 1) was performed 46 days after tumor
Approximately five weeks after lentiviral vector injection, cell injection. While all mice developed visible pulmonary lesions
transduced mice were injected subcutaneously with MDA-MB- in the control, NK4 HGF, and HGF groups, no metastasis could
435-4 cells, and tumor formation was monitored as already be detected in the decoy Met mice except for one animal. NK4
described. In striking contrast with the results obtained by ex-
HGF did not reduce metastasis incidence, but only metastasis
amining housekeeping physiological functions, analysis of tu-
number. Metastases in the HGF group were not only higher inmor formation (Table 1 and Supplemental Figure S9A) revealed
number, but also larger and more invasive compared to thethat mice expressing picomolar concentrations of decoy Met
empty vector group (see Supplemental Figure S9B for represen-were less permissive to xenograft implantation, as they dis-
tative images). Histological analysis of liver and kidney sectionsplayed longer latency and reduced penetrance. Also, tumor
did not reveal any obvious sign of pathology (not shown). Ingrowth was substantially inhibited, as measured by volume in-
contrast, consistent with a role of HGF in hemopoiesis (Galimicrease over time. Conversely, consistent with the previous
et al., 1994), bone marrow cell apoptotic index was found toin vivo data, mice expressing exogenous HGF displayed accel-
be increased by NK4 HGF and decoy Met, and decreased byerated tumor formation and a higher neoplastic growth rate. In
the NK4 group, tumor latency was slightly increased, and tumors HGF (Table 1).
68 CANCER CELL : JULY 2004
A R T I C L E
Table 1. Sustained picomolar plasma concentrations of decoy Met inhibit tumor growth and prevent metastasis without significantly affecting mouse
physiology
Tumor Tumor Number of Bone
Exp. group and FPC latency weight pulmonary WH time marrow RBC WBC PLT HGB
mouse no. (pM) (days) (g) metastases (days) a.i. (%) (106/ml) (103/ml) (103/ml) (mg/dl)
Empty vector #1 0.0 8.0 5.36 4.0 9.0 5.58 7.59 2.20 780.0 16.1
#2 0.0 10.0 5.40 17.0 11.0 5.06 7.60 2.37 650.0 17.0
#3 0.0 8.0 3.72 9.0 11.0 4.76 7.80 2.44 590.0 16.8
#4 0.0 14.0 1.68 8.0 9.0 5.56 7.10 2.71 620.0 17.0
#5 0.0 10.0 8.67 16.0 9.0 5.41 8.00 2.30 610.0 17.2
Average 0.0 10.0 4.97 10.8 9.8 5.27 7.62 2.40 650.0 16.8
SD 0.0 2.4 2.57 5.5 1.1 0.35 0.33 0.19 75.8 0.43
p N/A 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
HGF #1 100.2 6.0 9.98 23.0 9.0 4.05 9.10 2.47 700.0 16.8
#2 46.4 8.0 9.34 25.0 11.0 3.53 7.10 2.03 730.0 16.1
#3 40.8 8.0 6.98 16.0 11.0 3.95 9.10 2.71 640.0 17.2
#4 80.8 8.0 7.89 32.0 9.0 4.30 8.20 2.37 620.0 16.7
#5 70.2 6.0 7.32 18.0 9.0 3.81 8.10 2.37 650.0 16.8
Average 67.7 7.2 8.30 22.8 9.8 3.93 8.32 2.39 668.0 16.7
SD 24.6 1.1 1.30 6.30 1.1 0.29 0.83 0.24 45.5 0.4
p N/A 0.048 0.032 0.013 1.000 0.001 0.118 0.922 0.661 0.711
NK4 HGF #1 26.9 16.0 2.20 1.0 9.0 6.21 8.90 2.64 810.0 18.6
#2 36.8 14.0 2.59 5.0 11.0 5.88 9.10 2.71 720.0 18.2
#3 27.7 10.0 1.98 7.0 9.0 6.86 8.90 3.05 710.0 17.9
#4 24.2 18.0 3.26 13.0 11.0 6.25 8.90 2.54 830.0 17.9
#5 41.0 8.0 3.20 2.0 9.0 6.15 9.30 2.71 740.0 18.4
Average 31.3 13.2 2.65 5.6 9.8 6.27 9.02 2.73 762.0 18.2
SD 7.2 4.1 0.58 4.8 1.1 0.36 0.18 0.19 54.5 0.3
p N/A 0.176 0.084 0.151 1.000 0.002 0.001 0.028 0.028 0.001
Decoy Met #1 20.5 20.0 0.89 0.0 11.0 7.89 8.40 2.30 730.0 17.0
#2 21.9 12.0 1.71 2.0 9.0 7.97 9.40 2.10 670.0 18.8
#3 13.2 46.0 0.02 0.0 11.0 8.04 7.30 2.06 710.0 16.2
#4 50.5 20.0 0.52 0.0 11.0 7.14 7.50 2.74 690.0 17.0
#5 11.5 22.0 0.35 0.0 11.0 9.03 8.90 2.20 760.0 16.2
Average 23.5 24.0 0.70 0.4 10.6 8.01 8.30 2.28 712.0 17.0
SD 15.7 12.8 0.65 0.9 0.9 0.67 0.90 0.27 34.9 1.1
p N/A 0.044 0.007 0.003 0.242 0.001 0.150 0.431 0.135 0.679
CD-1 nu/ mice were injected i.v. with equal amounts of the indicated lentiviral vector and then assayed for the presence of the appropriate factor in
plasma (FPC, factor plasma concentration; see also Supplemental Figure S8 at http://www.cancercell.org/cgi/content/full/6/1/61/DC1). For each experi-
mental group, 5 mice expressing sustained picomolar levels of factor were selected, and then injected subcutaneously with tumor cells. The formation of
experimental tumors and of spontaneous metastases was analyzed as described in text. The same mice were subjected to a series of tests aimed at
determining several biological and clinical parameters (WH, wound healing; a.i., apoptotic index; RBC, red blood cells; WBC, white blood cells; PLT, platelets;
HGB, hemoglobin). Additional clinical parameters are analyzed in Supplemental Table S1.
Statistical significance (p value) was calculated by a two-tail homoscedastic Student’s t test. Significant values (p  0.05) are shown in italic. As revealed
by power calculation, this analysis detects variations corresponding to 2-fold the standard deviation (SD) with a power of 80%. N/A, not applicable.
Decoy Met synergizes with radiotherapy in inducing duced with empty vector partially regressed shortly after irradia-
tumor regression tion, but eventually relapsed and started to grow again within
HGF/Met signaling has been implicated in chemo- and radiore- a week (Figure 7B). Tumors transduced with HGF displayed
sistance of tumors (Fan et al., 1998). We therefore tested little if any radiosensitivity. In contrast, tumors transduced with
whether decoy Met could sensitize tumor cells to radiotherapy. decoy Met or NK4 HGF constantly regressed following irradia-
We irradiated lentiviral vector-transduced MDA-MB-435-4 tion and did not relapse. At the end of the experiment (day 24
cells in vitro, and determined their survival in the presence or after virus injection), tumors transduced with empty vector or
absence of recombinant HGF (Figure 7A). As expected, decoy HGF had increased their size by 2.2- and 6.7-fold, respectively,
Met efficiently abrogated the ability of HGF to protect tumor while tumors transduced with decoy Met or NK4 HGF had re-
cells against the toxic effects of radiation. NK4 HGF was also gressed by 4.7- and 2.8-fold, respectively. Thus, HGF protects
effective in this system, although to a lesser extent.
tumor cells against radiation; conversely, inhibition of the HGF/Next, we injected wild-type MDA-MB-435-4 cells into CD-1
Met pathway by decoy Met or NK4 HGF synergizes with radio-nu/ mice, and monitored animals for tumor appearance. Mice
therapy in inducing tumor regression.bearing tumors of approximately 100 mm3 were selected and
randomly divided into four groups (n  6) as described above.
DiscussionEach group was injected intratumorally with the appropriate
lentiviral vector on day 0 and 3, and mice were given a subcura-
In this study, we utilized a lentiviral vector-based gene transfertive irradiation dose (15 Gy) on day 6. After irradiation, tumor
volume was monitored for additional 18 days. Tumors trans- approach to investigate the role of HGF in tumor progression,
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clonal antibodies against HGF showed significant antitumoral
activity in experimental animals (Cao et al., 2001). However,
tumor inhibition was achieved only with a combination of at
least three different monoclonal antibodies, each for a distinct
epitope of HGF. Since each monoclonal antibody may have its
own specificity, pharmacodynamics, biodistribution, side ef-
fects, and dose/effect curve, the clinical application of this ap-
proach may encounter some complications. As a further con-
cern, neutralizing antibodies against HGF cannot prevent Met
activation induced by receptor overexpression, a very common
event in human cancer.
A different approach achieved downregulation of HGF
and/or Met in various experimental systems via U1snRNA/ribo-
zymes (Jiang et al., 2001). This technique makes use of a triple
combination of a U1snRNA, a hammerhead ribozyme, and an
antisense mRNA sequence to downregulate the messenger
RNA of a given gene. While this approach may be a valuable
tool in target validation studies that employ in vitro engineered
cell lines, it cannot have realistic clinical applications as of now,
since it is difficult to imagine how to achieve an efficient delivery
of the specific ribozyme to every single tumor cell in a patient.
Decoy Met, in contrast, is a secreted protein, which makes it
possible to achieve a paracrine and/or endocrine effect on all
the cellular components of the tumor by gene transfer to only
a small fraction of cells. Similar arguments apply to the use of
transmembrane, dominant-negative forms of Met (Firon et al.,
2000; Furge et al., 2001).
Recently, small molecule inhibitors against the Met kinase
have been developed (Sattler et al., 2003; Christensen et al.,
2003; Wang et al., 2003). These compounds prevent ATP from
binding to the ATP binding site of Met. This is an interesting
pharmacological approach that has achieved successful results
for other tyrosine kinases. However, small molecules inhibitors
also have their own limitations. First, no ATP analog will everFigure 7. Decoy Met sensitizes tumor cells to radiotherapy
be absolutely specific for a given tyrosine kinase, and thus,A: Lentiviral vector-transduced MDA-MB-435-4 cells were irradiated (0, 10,
toxicity is a big concern. A ligand-receptor interaction is, in20 Gy) in the presence or absence of recombinant HGF, and apoptosis
was determined after 48 hr. Apoptosis is expressed in arbitrary units (a.u.). contrast, extremely specific. Second, the biological activity of
B: Tumors of the same size (approximately 100 mm3) were injected with the small molecule inhibitors is dependent on a series of pharmaco-
indicated lentiviral vectors at days 0 and 3, and then irradiated at day 6
logical and pharmacodynamical parameters, such as biodistri-(15 Gy). Tumor volume was measured every 3 days. The numbers in red
bution, bioavailability, membrane permeability, clearance, andcorrespond to the days of lentivirus injection. LV, lentiviral vector.
metabolism, that have to be tested case by case in both preclini-
cal and clinical settings. In the case of the mentioned molecules,
no information on these parameters is yet available. Further-
and to explore the therapeutic potential of HGF/Met inhibitors more, none of the quoted studies analyzed metastasis, angio-
in antineoplastic therapy. genesis, or the effect of these anti-Met compounds on normal
As mentioned in the Introduction, multiple approaches have physiologic functions.
been previously attempted to inhibit HGF or Met in experimental Our preclinical data indicate that HGF levels greatly influence
systems. Among all the explored routes, the use of NK4 HGF the likelihood of developing metastases. Since HGF is ubiqui-
to displace HGF from Met is certainly the most thoroughly char- tous in tissues, and its plasma levels fluctuate in relation to
acterized and perhaps the most promising. The in vitro and particular physiological or pathological conditions, our findings
preclinical data presented in our study suggest, however, that have important implications in cancer therapy. For example,
decoy Met has several biochemical and biological advantages oncological patients who may potentially bear residual tumor
over NK4 HGF. First, decoy Met binds to HGF with approxi- cells—following primary tumor resection and/or chemother-
mately one log higher affinity than NK4 HGF binds to Met. apy—may be treated with anti-HGF agents to prevent the
Second, decoy Met can also inhibit Met activation induced by growth of such cells into manifest metastatic lesions. Alterna-
ligand-independent mechanisms. Third, decoy Met is signifi- tively, premalignant lesions for which surgical removal may not
cantly more effective than NK4 HGF in preventing metastasis, be appropriate could be held in check by HGF antagonists, in
order to prevent their malignant conversion. With regard to theseand has less pronounced systemic side effects.
In addition, decoy Met may also present some advantages possibilities, our data indeed demonstrate that decoy Met inhib-
its metastatic spread (1) independently of tumor size, (2) fromover other HGF/Met inhibitors. For example, neutralizing mono-
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every 3 days. At day 18, mice were killed by CO2 inhalation; tumors werepreexisting neoplastic lesions, and (3) as a preventive agent in
excised and weighed. Half of the tumor was embedded in Tissue-Tek OCTcirculating picomolar concentrations.
compound (Sakura Finetek, Torrance, California), and immediately frozen inWhile anti-HGF/Met drugs may be very efficient in pre-
liquid nitrogen. The second half of the tumor was embedded in paraffin.
venting tumor progression and metastasis, inhibition of the Tumor sections were used for tissue analysis. Lungs were embedded in
HGF/Met pathway per se may not be sufficient to cause tumor paraffin, serially sectioned, and stained with hematoxylin and eosin for histo-
regression. However, our results demonstrate that decoy Met logical analysis.
or NK4 HGF significantly sensitize tumor cells to irradiation, and
Systemic delivery of lentiviral vectorssynergize with radiotherapy in promoting tumor regression. This
Six-week-old nude female mice (6 mice/group) were injected through thefinding significantly broadens the therapeutic potential of HGF/
tail vein with the appropriate concentrated lentiviral vector (20 	g p24 HIVMet antagonists. In fact, anti-Met drugs may be used in combi-
equivalents/mouse). After three weeks, plasma concentrations of recombi-
nation with conventional chemo- or radiotherapy regimes to nant proteins were estimated by ELISA (see Supplemental Experimental
increase tumor sensitivity, thereby amplifying the therapeutic Procedures at http://www.cancercell.org/cgi/content/full/6/1/61/DC1). Mice
effect. expressing the lowest factor levels were excluded (1 mouse/group). Blood
samples were periodically obtained from these mice for up to 12 weeks.Our in vivo experiments show that systemic inhibition of
Plasma factor concentrations as well as a series of clinical parameters wereHGF/Met in adult animals does not significantly affect house-
determined. Approximately 5 weeks after lentiviral vector injection, MDA-keeping physiologic functions, but dramatically impairs tumor
MB-435-4 cells were injected subcutaneously as described above (2 

growth and prevents the formation of metastases. Although the 106 cells/mouse), and tumor burden was measured every 2 days. After an
substantial absence of side effects in our study does not rule observation time of 46 days (approximately 12 weeks after lentivirus injec-
out that more subtle differences could be detected by employing tion), mice were subjected to autopsy. Metastases were scored as described
a more powerful analysis, or that higher concentrations of inhibi- above. Tumors were excised, weighed, embedded in Tissue-Tek OCT com-
pound, and immediately frozen in liquid nitrogen. Bone marrow was har-tors could elicit more significant changes, our data demonstrate
vested from femora and suspended in PBS plus 2% FBS for cytologicalthat tumors are more sensitive to anti-Met drugs than normal
analysis. Livers and kidneys were embedded in OCT (to assess transductiontissues. The differential effect of HGF/Met inhibition on tumor
efficiency) and in paraffin (for histological analysis).
versus normal tissues could easily be explained by—and is
reasonably a proof of—the hypothesis that tumors are nothing Supplemental data
but “miniorgans” attempting to organize themselves and ex- For all experimental procedures not listed here above, please refer to the
Supplemental Experimental Procedures at http://www.cancercell.org/cgi/pand (Bissell and Radisky, 2001). With regard to this concept,
content/full/6/1/61/DC1.it is noteworthy to observe that hgf or met knockout mice die
in utero due to liver failure and placental defects, resulting from
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